What are the latest figures on the nocturia market’s size and projected CAGR?
The nocturia market size has grown strongly in recent years. It will grow from $2.87 billion in 2024 to $3.11 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to growing prevalence of cardiovascular diseases, increase in incidence of insomnia, rise in aging population, rising awareness of nocturia and related conditions, and increase in comorbidities.
The nocturia market size is expected to see strong growth in the next few years. It will grow to $4.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increasing prevalence of bladder obstruction disorders and urinary tract inflammation, rising incidence of excess urine production at night (nocturia) due to various risk factors, high intake of fluids contributing to nocturia, increasing awareness of nocturia’s connection to sleep disorders and kidney health, and aging population growth. Major trends in the forecast period include advancements in diagnostics, development of new drugs, increased research and investment in nocturia treatments, surgical and non-surgical treatment advancements, and adoption of personalized medicine.
Get Your Free Sample of The Global Nocturia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21232&type=smp
Which Market drivers have played a significant role in driving the nocturia market?
The growing prevalence of cardiovascular diseases is expected to propel the growth of the nocturia market going forward. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including conditions such as heart disease, stroke, and hypertension. The prevalence of cardiovascular diseases can be attributed to factors such as aging populations, sedentary lifestyles, unhealthy diets, smoking, excessive alcohol consumption, obesity, high blood pressure, high cholesterol, diabetes, and genetic predisposition. Patients with cardiovascular diseases often experience nocturia as a symptom, leading to higher demand for diagnosis and treatment solutions. As cardiovascular conditions continue to rise globally due to aging populations and unhealthy lifestyles, the need for effective nocturia management will grow. For instance, in May 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, heart disease in the US was responsible for 702,880 fatalities in 2022, representing 20% of all deaths in the United States. Annually, approximately 805,000 individuals experience a heart attack, with 605,000 being first-time cases and 200,000 occurring in those with a prior history. Therefore, the growing prevalence of cardiovascular diseases is driving the growth of the nocturia market.
What are the key segments within the nocturia market?
The nocturia market covered in this report is segmented –
1) By Drug: Anticholinergic Drugs, Desmopressin, Antibiotics, Antispasmodic, Other Drugs
2) By Indication: Mixed Nocturia, Low Nocturnal Bladder Capacity, Nocturnal Polyuria, Global Polyuria
3) By Causes: Urological Infection, Tumor Of The bladder, Diuretic Medications, Regular Alcohol Or coffee, Liver infection, Diabetes, Pregnancy, Other Causes
4) By End User: Hospitals, Home Care, Clinics
Subsegments:
1) By Anticholinergic Drugs: Oxybutynin, Tolterodine, Solifenacin, Darifenacin, Fesoterodine
2) By Desmopressin: Intranasal Desmopressin, Oral Desmopressin
3) By Antibiotics: Nitrofurantoin, Trimethoprim, Fosfomycin, Other Antibiotics
4) By Antispasmodic: Hyoscine Butylbromide, Flavoxate, Other Antispasmodics
5) By Other Drugs: Alpha-blockers, Beta-3 Agonists, Diuretics, Other Pharmacological Treatments
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/nocturia-global-market-report
Which key players are shaping the nocturia market?
Major companies operating in the nocturia market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Sanofi S.A, GlaxoSmithKline plc, Viatris Inc, Boehringer Ingelheim International GmbH, Otsuka Pharmaceutical Co. Ltd, Astellas Pharma Inc, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd, Ferring Pharmaceuticals A/S, Avadel Pharmaceuticals plc, UroGen Pharma Ltd, Sanwa Kagaku Co. Ltd., Urovant Sciences Inc, Serenity Pharmaceuticals LLC, Vantia Therapeutics Inc, AA Pharma Inc, Wellesley Pharmaceuticals Inc
Which transformative trends will shape the nocturia market landscape?
Major companies operating in the nocturia market are focusing on developing innovative products, such as orally disintegrating tablets, to enhance patient convenience and compliance. Orally disintegrating tablets (ODTs) are solid dosage forms that dissolve quickly in the mouth without needing water, making them ideal for patients with difficulty swallowing. For instance, in July 2024, Adalvo Limited, a Malta-based pharmaceutical company, launched Desmopressin ODT in Europe to treat conditions that cause the body to lose too much fluid, such as central cranial diabetes insipidus. This synthetic form of vasopressin tablet treats diabetes insipidus, excessive thirst and urination, and bedwetting by mimicking the natural hormone and limiting the amount of water eliminated in urine. It is also used to manage bleeding in mild to moderate hemophilia A and von Willebrand disease by promoting the release of blood clotting factors.
How do regional factors impact the nocturia market, and which region is the largest contributor?
North America was the largest region in the nocturia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nocturia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Nocturia Market Report 2025 Offer?
The nocturia market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Nocturia is a medical condition characterized by the need to wake up at night one or more times to urinate. It is considered a lower urinary tract symptom (LUTS) and can result from various underlying causes, including excessive fluid intake before bedtime, overactive bladder, urinary tract infections, diabetes, or prostate enlargement in men. Nocturia can significantly impact sleep quality and overall health, leading to fatigue and decreased daytime productivity.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21232
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
